FIELD: biotechnology.
SUBSTANCE: what is presented is a method for preparing a pharmaceutical agent for cancer immunotherapy. Method involves using osmotic tumor data, for which there is paired normal data, to obtain in silico a plurality of patient- and cancer-specific neoepitope n-measures cancer, selecting in silico n-measures to obtain a subset of sequences of neoepitopes, obtaining a synthetic n-dimensional peptide using information on the sequence of a subset of sequences of neoepitopes, use of synthetic n-dimensional peptide for recovery of recombinant antibody, obtaining information on sequence of complementarity determining region of recombinant antibody, obtaining a synthetic antibody using information on a complementarity determining region of a recombinant antibody and attaching a synthetic antibody to the therapeutic or diagnostic agent to obtain a pharmaceutical agent.
EFFECT: invention provides fast identification of patient-tumor antigens and in a short time obtaining antibodies aimed at such antigens for diagnostic or therapeutic application.
19 cl, 2 dwg, 1 tbl
| Title | Year | Author | Number |
|---|---|---|---|
| CELLS EXPRESSING CHIMERIC ACTIVATING RECEPTORS AND CHIMERIC STIMULATING RECEPTORS AND THEIR USE | 2018 |
|
RU2780020C2 |
| ANTI-CD 16 BINDING MOLECULES | 2006 |
|
RU2491294C2 |
| OBTAINING ANTIGEN-SPECIFIC T-CELLS | 2017 |
|
RU2745319C2 |
| CANCER TUMOUR RESPONSE DETERMINANTS FOR IMMUNOTHERAPY | 2014 |
|
RU2707530C2 |
| BIOLOGICAL MATERIALS AND APPLICATION THEREOF | 2006 |
|
RU2432363C9 |
| METHODS OF PREDICTING THE APPLICABILITY OF DISEASE-SPECIFIC AMINO ACID MODIFICATIONS FOR IMMUNOTHERAPY | 2018 |
|
RU2799341C2 |
| HIGH-AFFINITY ANTI-GD2 ANTIBODIES | 2014 |
|
RU2680267C2 |
| ANTIBODIES TO THE RELATED CANCER-EMBRYONIC ANTIGEN CELL ADHESION MOLECULE (CEACAM) | 2012 |
|
RU2650869C2 |
| IMMUNOREGULATORY VACCINE | 2013 |
|
RU2650709C2 |
| CDH3-PEPTIDE AND DRUG PREPARATION CONTAINING IT | 2008 |
|
RU2483078C2 |
